Mucosis B.V.
Meditech Center
L.J. Zielstraweg 1
9713 GX Groningen
The Netherlands
Trade Register / KvK: 02096219
We strive to make innovative vaccines by translating excellent scientific research into a robust vaccine technology to create better, painless and needle-free vaccines to combat parasitic, bacterial and viral infections. We are dedicated to achieving these goals by motivating talented researchers to excel and by collaborating with the best academic and industrial partners in the field.
31.05.10 Mucosis receives financial support from the Dutch government for its FluGEM program
more >
27.04.10 Mucosis appoints Dr. Roberto Grimandi as chief medical officer
more >
22.09.09 Mucosis receives key US patent covering its Mimopath™ technology
more >
28.01.09 Mucosis B.V. and PATH start development of pneumococcal vaccines
more >
15.12.08 Mucosis B.V. and TNO announce flu vaccine research and development partnership.
more >
10.12.07 News article in “Het Financieele Dagblad”.
more >
06.11.08 Mucosis B.V. appoints Dr. Govert Schouten as CEO. more >
10.09.07 Mucosis raises € 3 million in first financing round more >